This Treatment Program is 100% Non-Toxic, Non-Invasive and has no Side Effects. Once this Program is accepted by the Medical Community as beneficial and safe, it could potentially be the first treatment protocol every DIPG Doctor in the world prescribes new Patients since it preventsgrowth and progression of the disease - all while preserving their quality of life.
However, to gain that acceptance and be implemented as common practice, our Treatment Protocol must be researched in a clinical environment - The Cancer Wellness Clinic is providing that clinical environment.
The Main Supplement in the Program is TBL-12. This Product is classified as an Orphan Drug in the United States for the Treatment of Multiple Myeloma. Gaining this designation means that research and clinical trials proving its efficacy and safety for patients have been conducted and published. We can rely on this data for initial studies, but specific DIPG Studies are required.
Toxicity Study - TBL-12 has been tested in an animal studies to show its toxicity level. It has been proven that TBL-12 is non-toxic even at extremely high doses. We have Study results from 2 research facilities - most recently NOVA University in Miami, FL.
TBL12 In Vitro Studies
"In Vitro Studies have shown TBL-12 inhibits the proliferation, migration and invasion of human prostate cancer cells of Prostate Cancer Cells."
A Gastric Cancer study demonstrated "that TBL-12 not only reduces the migration and invasion of gastric cancer HGC-27 cells, but also inhibits cell proliferation and promoted apoptosis. The inhibitory capacity increases with increasing drug concentration. It is anticipated that TBL-12 not only has a role in promoting apoptosis but also has influence on the metastasis of gastric cancer, thus providing a theoretical basis for the application of TBL12 in the treatment of tumors."
Studies conducted by NYU on TBL-12 concluded "studies suggest thatTBL-12 is effective in reducing myeloma cell growth in a dose dependent manner. Based on the cellular changes observed it seems that TBL-12 may induce damage to the cancer cell membrane, associated with cell cycle arrest and suppression of cell division. This concentration is also found to be effective in inhibiting prostate and cervical cancer cell growth by >50%. Although thee correlative study findings from cell based assays support the anticancer effects of TBL-12, investigating the cellular changes induced by TBL-12 could reveal several molecular targets in different human cancers."
Blood Brain Barrier Penetration
The reason that brain tumors are the most difficult tumors to treat is because the brain has its own protective "bubble" in order to keep infections out - and ironically also keeps out medications trying to kill the tumors. This is why penetrating the Blood Brain Barrier is crucial.
TBL-12 and DIPG Cancer Cells - In Vitro Research
TBL-12 has been researched in vitro on many cancer cell lines, including Multiple Myeloma, Prostate, Cervical, and others with promising results (referenced above). We are currently seeking DIPG Cell Lines for similar studies in order to directly test the effects of TBL-12 on DIPG Cells in vitro.
A research facility in the US has agreed to conduct a new LD50 Toxicity Study using the latest methodology for future Clinical Trial usage.
Over the past 30 years, DIPG patients have participated in more than 250 Clinical Trials. None of these trials have shown any benefit in either the likelihood of survival or the medial tenth of survival. In fact, they have been more detrimental to the patients and their families due to the side effect from which the children suffer.
It is time for a whole new approach to this disease. TBL-12 and the Program the Cancer Wellness Clinic has instilled is that new approach. It is all-natural, non-toxic, non-invasive and has zero adverse side effects. It can be administered in a Clinical Environment as well as a Home Environment.
The Clinical Trial protocol is being developed in conjunction with, and monitored by, several Universities whose research staff oversee the work.
The data collected from the Clinical Trial will be reviewed and submitted publicly for the DIPG Research Community.
We are committed to finding a cure for this disease - and we are more than willing to share our findings with anyone wanting information. Results will be posted on this webpage, published in medical journals, and given to anyone asking.